Trevi Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update

About this update from Trevi Therapeutics, Inc.

[{"type":"text","content":"Management to host a conference call and webcast today at 4:30 p.m. EDT\nNEW HAVEN, Conn., Nov. 10, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis, today announced financial results for the quarter ended September 30, 2022, as well as provided business updates.\n\n \n \n \n \n \n \n\n \n\"I am incredibly proud of the progress our team has made this year with two positive data read-outs in our indications and subsequent successful financings,\" said Jennifer Good, President and CEO of Trevi Therapeutics. \"At our R&D Day in September, we announced the final positive results from our Phase 2 CANAL trial of Haduvio for the treatment of chronic cough in IPF that demonstrated a strong magnitude of effect on cough and statistically significant data for the primary efficacy endpoint and other key secondary endpoints. We have approximately $126 million in cash, cash equivalents, and investments at the end of the quarter, which we plan to use to fund further development in our targeted cough indications.\"\nKey Business Updates\nPhase 2 CANAL trial of Haduvio for the treatment of chronic cough in IPF As previously announced, the Phase 2 CANAL trial results from the full analysis set (N=38) achieved statistical significance on the trial's primary endpoint and showed Haduvio subjects had a 75.1% reduction in daytime cough frequency at the end of the treatment period vs. study baseline, compared to placebo subjects who had a 22.6% reduction, a 52.5% placebo-adjusted change (p","length":3282,"tagName":"div"}]

More updates from Trevi Therapeutics, Inc.